IMPACT OF METFORMIN ON OSTEOPROTEGERIN LEVELS IN POLYCYSTIC OVARIAN WOMEN.

Metformin is an important agent in the treatment of polycystic ovary syndrome (PCOS) treatment. Osteoblast express osteoprotegerin (OPG) which has integral effects on bone metabolism nexus. This cross-sectional research sought to identify the impact of metformin therapy on serum level osteoblast express osteoprotegerin and prolactin in women with polycystic ovary syndrome. Methods: 30 patients with PCOS and 30 controls. The current study revealed that prolactin levels were increased in PCOS group compared to control group which is highly significant. While after treatment with metformin prolactin level was reduced significantly in than before treatment. Osteoprotegerin concentrations were considerably dropped in the PCOS group contrasted with the control group. Conversely, serum osteoprotegerin in metformin-treated group were higher compared to PCOS group. Osteoblast express osteoprotegerin level increased after 3 months of treatment with metformin in women with polycystic ovary syndrome.

SERUM LIPOCALIN-2, AND FETUIN-A LEVELS IN PATIENTS WITH ALZHEIMER'S DISEASE.

Alzheimer's disease is a neurodegenerative disease leading to a progressive and irreversible loss of mental functions. It is characterized by 3 stages according to the evolution and the severity of the symptoms. The authors of the present study aimed to investigate the levels of serum lipocalin-2, fetuin-A, and TNF-α in patients with Alzheimer's disease. 56 patients with Alzheimer's disease (the first group), and another 25 healthy volunteers (control group) were enrolled in this cross-sectional study. The serum levels of lipocalin-2, fetuin-A, and Tumor necrosis factor (TNF-α) were determined with the use of the ELISA method. There was a significant elevation in serum lipocalin-2, and TNF-α levels in the AD group (88.68±32.1) and(42.28±5.05) respectively, compared to the control group (63±28.5), and (35.19±5.07) respectively, [p<0.001]. A significant increase in serum concentration of lipocalin, TNFa with a reduction of fetuin-A could be considered an important phenomenon used for follow-up or prognosis and diagnosis of Alzheimer's disease.